May 22, 2025

New FDA-Approved Topical Foam for Scalp Psoriasis

The FDA has approved roflumilast (ZORYVE) foam 0.3% for once-daily treatment of plaque psoriasis in patients aged 12 and older, including hard-to-treat scalp and body areas..

Conexiant

May 22, 2025

Voices on the Go: Top Podcasts for Physicians

Physicians are tuning to podcasts that combine clinical insight, career development, and storytelling.

Conexiant

May 19, 2025

Phase 3 Data Backs Roflumilast Foam

Roflumilast foam was found to improve scalp and body psoriasis symptoms with favorable tolerability in patients aged 12 years and older.

Conexiant

September 17, 2024

Can Hair Dye Cause Retinopathy?

Aromatic amines may cause long-term RPE dysfunction

Conexiant

July 26, 2024

Healing and Owing: U.S. Health Workers' $150 Billion Debt Dilemma

A new study exposes the alarming levels of medical and educational debt burdening U.S. health care workers, with debt disproportionately affecting women, Black workers, and those in lower-paying fields.

Conexiant

January 15, 2025

Bertagnolli to Exit NIH Director Role

NIH director, Dr. Monica M. Bertagnolli, is stepping down after launching major initiatives in women's health and long COVID research, indicating optimism for their continuation under new leadership.

Conexiant

July 31, 2024

Alopecia Areata Linked to Mental, Autoimmune Risks

New study published in JAMA Dermatology reveals that patients newly diagnosed with alopecia areata face a higher risk of developing psychiatric and autoimmune disorders.

Conexiant

February 07, 2025

Hematologic Indicators Linked to Alopecia Areata Severity

Researchers analyze hematological ratios in alopecia areata severity assessment.

Conexiant

October 11, 2024

Skin Pigmentation: Rethinking Drug Efficacy

With skin pigmentation influencing drug binding and potentially altering therapeutic outcomes, understanding melanin's role in pharmacokinetics is key to advancing equitable treatments.

Conexiant